Mostrar el registro sencillo del ítem
dc.contributor.author | Garcia-Rios, Estefani | |
dc.contributor.author | Leivas, Alejandra | |
dc.contributor.author | Mancebo, Francisco Jose | |
dc.contributor.author | Sánchez-Vega, Laura | |
dc.contributor.author | Lanzarot, Diego | |
dc.contributor.author | Aguado, José María | |
dc.contributor.author | Martinez-Lopez, Joaquin | |
dc.contributor.author | Paciello, María Liz | |
dc.contributor.author | Perez-Romero, Pilar | |
dc.date.accessioned | 2022-05-24T09:42:05Z | |
dc.date.available | 2022-05-24T09:42:05Z | |
dc.date.issued | 2022-03-09 | |
dc.identifier.citation | Biomedicines. 2022 Mar 9;10(3):630. | es_ES |
dc.identifier.issn | 2227-9059 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14481 | |
dc.description.abstract | In order to demonstrate the feasibility of preparing clinical-grade SARS-CoV-2-specific T-cells from convalescent donors and the ability of these cells to neutralize the virus in vitro, we used blood collected from two COVID-19 convalescent donors (before and after vaccination) that was stimulated with specific SARS-CoV-2 peptides followed by automated T-cell isolation using the CliniMacs Prodigy medical device. To determine cytotoxic activity, HEK 293T cells were transfected to express the SARS-CoV-2 M protein, mimicking SARS-CoV-2 infection. We were able to quickly and efficiently isolate SARS-CoV-2-specific T lymphocytes from both donors before and after they received the Pfizer-BioNTech vaccine. Althoughbefore vaccination, the final product contained up to 7.42% and 30.19% of IFN-γ+ CD3+ T-cells from donor 1 and donor 2, respectively, we observed an enrichment of the IFN-γ+ CD3+ T-cells after vaccination, reaching 70.47% and 42.59%, respectively. At pre-vaccination, the isolated SARS-CoV-2-specific T-cells exhibited cytotoxic activity that was significantly higher than that of unstimulated controls (donor 2: 15.41%, p-value 3.27 × 10-3). The cytotoxic activity of the isolated SARS-CoV-2-specific T-cells also significantly increased after vaccination (donor 1: 32.71%, p-value 1.44 × 10-5; donor 2: 33.38%, p-value 3.13 × 10-6). In conclusion, we demonstrated that SARS-CoV-2-specific T-cells can quickly and efficiently be stimulated from the blood of convalescent donors using SARS-CoV-2-specific peptides followed by automated isolation. Vaccinated convalescent donors have a higher percentage of SARS-CoV-2-specific T-cells and may be more suitable as donors. Although further studies are needed to assess the clinical utility of the functional isolated SARS-CoV-2-specific T-cells in patients, previous studies using the same stimulation and isolation methods applied to other pathologies support this idea. | es_ES |
dc.description.sponsorship | This work was supported by MutuaMadrileña Foundation (2020/0056), “Plan Nacional de I+D+I” and Instituto de Salud Carlos III (COVID-19 Research Call COV20/00181), Subdirección General de Redes y Centros de Investigación Cooperativa, Spanish Ministry of Science and Innovation, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016)—co-financed by the European Development Regional Fund (EDRF) and the European Social Fund (ESF) “A way to achieve Europe-The ESF invests in your future “, REACT-EU grant from the Comunidad de Madrid to the ANTICIPA (Complutense University, Madrid). E.G.-R. is supported by the Sara Borrell Program (CD18CIII/00007), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades. F.J.M. is supported by the PFIS Program (F18III/00013), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | T-lymphocytes | es_ES |
dc.subject | Cytotoxicity | es_ES |
dc.subject | M protein | es_ES |
dc.title | Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19 | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 35327433 | es_ES |
dc.format.volume | 10 | es_ES |
dc.format.number | 3 | es_ES |
dc.format.page | 630 | es_ES |
dc.identifier.doi | 10.3390/biomedicines10030630 | es_ES |
dc.contributor.funder | RETICS-Investigación en Patología Infecciosa (REIPI-ISCIII) (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Social Europeo (ESF/FSE) | es_ES |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Plan Nacional de I+D+i (España) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Comunidad de Madrid (España) | es_ES |
dc.contributor.funder | Fundación Mutua Madrileña | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/biomedicines10030630 | es_ES |
dc.identifier.journal | Biomedicines | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0016%2F0004/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN PATOLOGÍAS INFECCIOSAS/ | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/COV20/00181 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CD18CIII/00007 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/F18III/00013 | es_ES |